Aigner_Andreas Posted - 1 day ago

#GoldenCross $FMS at 21.27 R5 HiLo 49% T1Y 21 hold DIV 5.00% #Fresenius #stocks #trading #finance #market

Youngandhappy Posted - 05/30/24

@Qutiaw @steveboehm News is imminent. News of improved child followed by Proxy passage, all 6, & Vantive deal of some sort. If $FMS or $NUWE or $DVA news precedes those 3 ?major news items…..pop to $10 is possible SB and you know it. Come on….give it to me! MBBBB, 🕺 B

juniorminting Posted - 05/30/24

$HUMA $FMS I think 1 contract with DOD will have them adding on to manufacturing capacity .imo

juniorminting Posted - 05/29/24

$HUMA $FMS

Youngandhappy Posted - 05/26/24

$ICU $NUWE $FMS $BAX MedPage Today’s: AI response to the my 👀! The Quelimmune Selective Cytopheretic Device is a new medical device approved by the FDA for treating acute kidney injury (AKI) due to sepsis or septic conditions in pediatric patients weighing 10 kg (around 22 pounds) or more who require kidney replacement therapy (KRT).The device received a Humanitarian Device Exemption (HDE) approval order from the FDA. It is the first product in SeaStar Medical's Quelimmune product family. The Quelimmune device works by using immunomodulating technology to selectively target and transition proinflammatory neutrophils and monocytes to a reparative state during continuous renal replacement therapy. This helps reduce the hyperinflammatory environment, including the cytokine storm that can cause inflammation, organ failure, and potential death in critically ill patients. The device is designed to be integrated with continuous renal replacement therapy hemofiltration systems. It selectively targets the most highly activated proinflammatory neutrophils and monocytes, which are then returned to the bloodstream, signaling the body to decrease its inflammatory response and focus on repair. The approval was supported by pooled data from two small FDA-funded studies involving a total of 22 pediatric patients. These studies showed a significant reduction in mortality rates, no device-related serious adverse events or infections, and no dialysis dependency by day 60 of device use. MBBB

GoodTidings Posted - 05/24/24

@PaulNipkow Great analytical outline... I prefer $FMS as a buyer but no indications from that part sofar... It's only speculation... We'll see what the future gone hold... Any buyout will squeeze out shorts though cause all shares will need to be returned to owners!!! That would be a great side-effect!!! 😁😁😁

Unitypal Posted - 05/24/24

$FMS $BAX $ICU $NUWE The Stars are aligning. All are ready. 4 - Peat. 4+4

HeyDuggee Posted - 05/24/24

MDAI is a gamechanging AI technology that provides immediate wound healing prediction using its proprietary and patented technology. • Breakthrough technology with no competitors. • $250m total US Government contracts awarded – NON DILUTIVE FUNDING! • Under $30m market cap • Around 52% of shares held by insiders. • Around 21% of shares held by institutions. • LOW FLOAT • Deploying their main product, DeepView®, in the UK. Initial feedback from the medical professionals has been excellent. • Initiating commercial transactions in the UK in 2nd half of this year. • In the U.S, total medical costs for diabetic foot disease ranges from 9 to 13 billion annually. Diabetic Foot Ulcers (DFU) is only one of the current clinical applications. • 10 US patents and 10 foreign patents (more in the pipeline) • Clinical applications to be possibly expanded to other medical programs. $AMN $FMS $QIPT DYOR - share price won’t be this cheap for too long.

Stock_Titan Posted - 05/21/24

$FMS Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024 https://www.stocktitan.net/news/FMS/fresenius-medical-care-showcases-leadership-and-innovation-in-kidney-uu8ni7ohmgc6.html

Youngandhappy Posted - 05/17/24

@Jizzledrizzle We need to start a pool. $DVA $FMS $BAX $NUWE. Nuwellis is 3-1! Baxter even! Fresenius 2-1! Davita 1.5-1! Lay down your bets Ladies and Gentlemen. WHO IS THE Merge With? THIS NEEDS TO BE ADDED TO THE PROXY VOTE ON 06/04/2024! Let’s get MAXIM’s Dude to hold the money and pay the winners! 4MB

StockInvest_us Posted - 05/17/24

Signal alert: $FMS - Overbought Trend Short (Overvalued) https://stockinvest.us/l/Gzu7xTyoYO

Youngandhappy Posted - 05/16/24

$NUWE $ICU 4 x 2 Revolutionary INTENSIVE CARE UNIT medical device companies working in tandem through the commercialization of the Quelimmune SCD-PED & Nuwellis’s newest, state of the art, fluid filter. Both are destined for notoriety in the intensivist domain! $BAX, $FMS, $DVA. All 3 giant stalwarts are jockeying for position. 4MB

Youngandhappy Posted - 05/16/24

$ICU I have reached out to $FMS about the # of devices produced to date, shipments to $NUWE and their production schedule for the next month for the Quelimmune SCD-PED. These home units are interesting by $BAX. These two manufacturers are in our present and in our future, IMHO! Tweeked Current Dialysis devices in combo with the Quelimmune SCD = BlindinglyBright, MindBogglingly, UnlimitedPossibilities every day in and every day out filled with life bettering medical technology serving All of Humanity! MN

Stock_Titan Posted - 05/16/24

$FMS Fresenius Medical Care Annual General Meeting: Company makes significant progress in its Transformation Efforts and confirms its ambitious 2024 Growth Targets https://www.stocktitan.net/news/FMS/fresenius-medical-care-annual-general-meeting-company-makes-djf9t684svcy.html

juniorminting Posted - 05/15/24

$HUMA $FMS $SPX $QQQ

JakeDelToro Posted - 05/14/24

$ICU In all honesty, SeaStar could (and should) get bought out by $FMS end of 2024 or early 2025. Fresenius divested approximately $500 million of dialysis business end of 2023. SeaStar has Collins on the BOD who is ex-CMO of Fresenius. If SCD-ADULT shows removal of dialysis dependency come interim analysis, that'd be a great scoop by FMS. A german company would give them a quick process to European expansion, as SeaStar has already made many moves in NA. No matter how bullish I am about that, the company has <$5m cash and needs to ramp up operations for commercialization and enrollment. I don't see how they make it through July without raising.

Youngandhappy Posted - 05/14/24

@jameswills BO/Merger! King Size with $BAX, $FMS, $DVA! One or d’otha! 4MB

JakeDelToro Posted - 05/12/24

@Qutiaw Absolutely. I put together a reddit DD awhile back about how $FMS would be an ideal candidate for buying $ICU around the interim analysis of SCD-ADULT. They divested like $500 mil worth of dialysis business in the fall last year, so their balance sheet is juicy. They’ve got allan collins on the board who I think was CMO or CEO at fresenius. And if it turns out SCD-ADULT continues to show complete removal from dialysis dependency like they have seen in the limited trials, Fresenius should jump on it end of 2024 or early 2025.

JakeDelToro Posted - 05/12/24

$ICU So am I understanding this correctly? $FMS had right of first refusal to be the distributor (they are already the supplier for key components) of Quelimmune. SeaStar has a license agreement with $NUWE to be the exclusive distributor, where Nuwellis will pay milestone payments to Fresenius, which was updated end of 2023. So Fresenius said no to being the distributor and will let Nuwellis handle distribution, but will require milestone payments in exchange, since they had right of first refusal? Presumably, if Fresenius had elected to be the exclusive distributor, they wouldn't have allowed the agreement with Nuwellis to come into effect. Or had it updated with the milestone payments from distributor to supplier?

Youngandhappy Posted - 05/11/24

@Disco007 One half of their clinic chairs will be Quelimmune SCD chairs by 2030. A larger percentage? Possibly! 1-3 hr. duration treatment, weekly, biweekly, monthly, every 3rd day, every other day, who knows right now. Modified treatment from the current 24 hour treatment for 3-7 days while in the ICU for AKI, Sepsis, Cardiac, Liver, Lung! -150+ autoimmune disorders! -Crohn’s, IBS, Lyme, RA, Alzheimer, MS(even a possibility)! - All are hyperinflammatory. -All! ——-It is such a natural, no brainer retrofit for Fresenius and Davita. ——-FDA trials….probably necessary for the modified device and/or the modified calcium substrate, if required. -Patents, if necessary, incoming -BDD numbers 4-10, incoming. -The Vantive $BAX spinoff is the perfect merge. -$FMS and $DVA are both perfect partnerships. JUST THINKING OUT-LOUD HERE DiscoCowboyBondMan! Beyond 4MB

Youngandhappy Posted - 05/11/24

@Torp @indepth1 Where have you been ID1? Great post. The Government, the FDA, the NIH, the US Armed Forces, the SAB member hospitals, NASDAQ, DOW Chemical, $BAX ?, $FMS, $NUWE, their partner $DVA, LMFA, Me, mi Espousa, @Disco007 are all on board. Let’s all set sail for Bermuda in ‘26! 4MB

StockInvest_us Posted - 05/10/24

Signal alert: $FMS - PivotPoint bottom https://stockinvest.us/l/yedxZVydGm

Youngandhappy Posted - 05/10/24

$FMS $ICU. Instead of $BAX, whatevah!!!!

Blastus Posted - 05/09/24

$ICU the daily is looking pretty bullish for $NUWE They've been producing a good string of PR's. All across the board with $DVA $FMS $BAX with good Earning's Reports and PR's of progress, this entire sector is heating up. With $ICU cleaning some skeleton's out of their closet, it's only a matter of time before share price starts ascending from news of sales, contracts. It's still a long game here with substantial growth in the years to come. Getting compliance at $1 will draw a lot of attention from Institutions and again at $5 with more institutions & ETF's who have a minimum $5 standard. All those players hold for years and that's what this company needs most. Long term holders who buy up any and all dips through it's staircase climb. The conversion of warrants to shares is crucial for compliance I believe. Will Maxim's MM continue to short share price into oblivion and force an RS on their own shares? Wouldn't be very smart if they did.

Youngandhappy Posted - 05/07/24

@TU6637 Do you own these? $DVA $FMS $ICU $NUWE ?

Stock_Titan Posted - 05/07/24

$FMS Fresenius Medical Care starts the year with strong earnings growth https://www.stocktitan.net/news/FMS/fresenius-medical-care-starts-the-year-with-strong-earnings-0kwk5aleyyqo.html

Youngandhappy Posted - 05/03/24

@Torp @Zydecoshuffle $FMS, their 1 month chart is mega bullish. Investors liked the SA clinics sell off apparently.

jameswills Posted - 4 weeks ago

$FMS $ICU what is this proxy vote people keep referring to?

Unitypal Posted - 4 weeks ago

$FMS

Unitypal Posted - 4 weeks ago

$FMS $ICU Fresenius 1 month chart is bullish AF! They are SeaStar’s production subcontractor. What else is coming? The Proxy vote, SeaStar Medical’s, will be announced tomorrow, I believe. Major shares owner will be revealed shortly thereafter. It is sure to pass. You have time.